Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
The Neurologist 8:227-236, Frohman,E.,et al, 2002
Herpes Simplex & the Human Nervous System
Milit Med 140:765, Finelli,P.F., 1975
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008
Treatment of Early Onset Multiple Sclerosis With Subcutaneous Interferon Beta-1a
Neurol 64:888-890, 778, Pohl,D., et al, 2005
Interferon Beta but not Glatiramer Acetate Therapy Aggravates Headaches in MS
Neurol 59:636-639, Pollmann,W.,et al, 2002
Multiple Sclerosis, Side Effects of Interferon Beta Therapy and Their Management
Neurol 53:1622-1627, Walther,E.U.&Hohlfeld,R., 1999
Interferon-B-1a in Relapsing-Remitting Multiple Sclerosis:Effect on Hypointense Lesion Volume on T1 Weighted Images
JNNP 67:579-584, Gasperini,C.,et al, 1999
Clinicopath Conf
Subacute Sclerosing Panencephalitis, Case 15-1998, NEJM 338:1448-1456998., , 1998
Side Effect Profile of Interferon Beta-1b in MS:Results of an Open Label Trial
Neurol 46:552-554, Neilley,L.K.,et al, 1996
Chronic Systemic High-Dose Recombinant Interferon Alfa-2a Reduces Exacerbation Rate & MRI Signs in MS
Neurol 44:406-413, Durelli,L.,et al, 1994